Lupin launches generic Potassium Chloride for oral solution USP post USFDA nod

Mumbai: Pharma major Lupin Limited (Lupin) recently announced the launch of Potassium Chloride (KCl) for Oral Solution USP, 20 mEq, having received an approval from the United States Food and Drug Administration (U.S. FDA) earlier.

Lupin’s Potassium Chloride for Oral Solution USP, 20 mEq, is the generic equivalent of Pharma Research Software Solution, LLC’s Potassium Chloride for Oral Solution USP, 20 mEq, and is indicated for the treatment and prophylaxis of hypokalemia with or without metabolic alkalosis in patients for whom dietary management with potassium-rich foods or diuretic dose reduction is insufficient.

Also Read: Lupin unveils a generic version of Sun Pharma Westcort Cream to treat skin conditions

Potassium Chloride for Oral Solution USP, 20 mEq, had an annual sales of approximately USD 90 million in the U.S. (IQVIA MAT September 2019).

Headquartered in Mumbai, Lupin develops and delivers a wide range of branded and generic formulations, biosimilar products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global position in the Anti-TB segment.

Also Read: Lupin gets USFDA nod for a generic equivalent of Zyflo CR Extended-Release Tablets to treat prophylaxis, asthma